Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

INVOKANA 300 MG COMPRIMIDOS RECUBIERTOS CON PELICULA - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/INVOKANA 300 MG COMPRIMIDOS RECUBIERTOS CON PELICULA

Approved

STANDARD

INVOKANA 300 MG COMPRIMIDOS RECUBIERTOS CON PELICULA

Janssen-Cilag International N.V🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Jun 6, 2024
Approval ID: 2e99d3b09a4681f1
Company: Janssen-Cilag International N.V
Type: Standard

Approval Details

Approval Id: 2e99d3b09a4681f1
Drug Cima Aemps Name: INVOKANA 300 MG COMPRIMIDOS RECUBIERTOS CON PELICULA
Register Number: 113884006IP1
Holder Company Name: Janssen-Cilag International N.V
Marketing Company Name: Difarmed S.L.U.
Holder Company Detail Path: /organization/janssen-cilag-international-nv
Authorization Date: 2024-06-06
Dosage Form: COMPRIMIDO RECUBIERTO CON PELÍCULA
Dose: 300 mg
Route Of Administration: VÍA ORAL
Prescription Type: Medicamento Sujeto A Prescripción Médica
Commercialized: Yes
Company Name: Janssen-Cilag International N.V
Company Detail Path: /organization/janssen-cilag-international-nv

Company Information

Pharmaceutical Company Name: Janssen-Cilag International NV
Country Name: Belgium

Active Ingredients

CANAGLIFLOZINA

300 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Jun 6, 2024

Approval ID

2e99d3b09a4681f1

Type

Standard

Back to CIMA-AEMPS Approvals